Cite
HARVARD Citation
Ferrannini, G. et al. (n.d.). Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial. European heart journal. p. . [Online].